Minimally invasive thoracoscopically-guided right minithoracotomy versus conventional sternotomy for mitral valve repair: a multicentre randomised controlled trial (UK Mini Mitral).

PROTOCOL

Chief Investigator: Mr Enoch Akowuah
Consultant Cardiothoracic Surgeon
The James Cook University Hospital
South Tees Hospitals NHS Foundation Trust
Marton Road,
Middlesbrough, TS4 3BW
Tel: 01642 850850 (ext. 53922)

Clinical Trials Unit: Newcastle Clinical Trials Unit
Murray Building
James Cook University Hospital
Marton Road
Middlesbrough
TS4 3BW
Tel: 01642 854 638

Funder: National Institute of Health Research – Health Technology Assessment Programme (project reference 14/192/110)

Sponsor: South Tees Hospitals NHS Foundation Trust

Trial Identifiers: ISRCTN: ISRCTN13930454

Table of Contents

1. Protocol Synopsis .................................................................................................................. 5
2. Trial Flow Diagram .............................................................................................................. 10
3. Abbreviations ......................................................................................................................... 11
4. Introduction ............................................................................................................................ 12
  4.1. Background ......................................................................................................................... 12
  4.2. Choice of Comparators ....................................................................................................... 12
  4.3. Current Evidence Supporting the Rationale for the Trial .................................................. 14
5. Trial Objectives ....................................................................................................................... 16
  5.1. Primary Objective ............................................................................................................... 16
  5.2. Primary Economic Objective ........................................................................................... 16
  5.3. Secondary Objectives ....................................................................................................... 16
6. Trial Design ............................................................................................................................ 17
  6.1. Summary ............................................................................................................................ 17
  6.2. Inclusion Criteria ............................................................................................................... 17
  6.3. Exclusion Criteria ............................................................................................................. 17
  6.4. Setting ............................................................................................................................... 17
  6.5. Expertise of Cardiac Surgeons ......................................................................................... 19
  6.6. Primary Outcome .............................................................................................................. 19
  6.7. Primary Economic Outcome .......................................................................................... 19
  6.8. Secondary Outcomes ....................................................................................................... 19
  6.9. Process Outcomes .......................................................................................................... 20
7. Trial Procedures ...................................................................................................................... 22
  7.1. Summary of Trial Assessments ....................................................................................... 22
  7.2. Recruitment ....................................................................................................................... 24
  7.3. Informed Consent ............................................................................................................. 24
  7.4. Eligibility check ............................................................................................................... 24
  7.5. Screen Failures .................................................................................................................. 24
  7.6. Randomisation .................................................................................................................. 24
  7.7. Blinding ............................................................................................................................. 25
  7.8. Informing General Practitioners of Patient Participation ............................................... 25
  7.9. Withdrawal ....................................................................................................................... 25
  7.10. Baseline Assessments ..................................................................................................... 26
    7.10.1. Cardiovascular and Significant Current and Past Medical History ............................ 26
    7.10.2. NYHA Class ............................................................................................................... 26
    7.10.3. Physical Assessment ................................................................................................. 26
    7.10.4. Current Medications ............................................................................................... 26
7.10.5. Demographic Information .................................................................................. 26
7.10.6. Pregnancy Test ................................................................................................. 27
7.10.7. Echocardiogram .............................................................................................. 27
7.10.9. EuroSCORE ...................................................................................................... 28
7.10.10. SF-36v2, EQ-5D-5L ...................................................................................... 28
7.10.11. Accelerometer ................................................................................................. 29
7.11. Surgical Interventions .......................................................................................... 29
7.11.1. Conventional Surgery ....................................................................................... 29
7.11.2. Minimally Invasive Surgery ............................................................................. 30
7.11.3. Concomitant Procedures ................................................................................. 30
7.11.4. Anaesthetic Protocol ......................................................................................... 30
7.11.5. Intra-operative Assessments ............................................................................. 30
7.12. Post-operative Assessments ............................................................................... 31
7.12.1. Post-operative Blood Loss ............................................................................... 31
7.12.2. Further Surgery ............................................................................................... 31
7.12.3. Wound Pain Score ......................................................................................... 31
7.12.4. Length of Hospital Stay Following Index Surgery ........................................... 31
7.12.5. Transfusion of Blood and Blood Products ....................................................... 31
7.12.6. Routinely collected data and NICOR Data ....................................................... 32
7.12.7. Healthcare Utilisation Questionnaire .............................................................. 32
7.13. Follow-up Assessments ...................................................................................... 32
8. Safety Reporting ...................................................................................................... 34
8.1. Adverse Events ...................................................................................................... 34
8.2. Serious Adverse Events ......................................................................................... 34
8.3. Foreseeable Adverse Events ............................................................................... 34
8.4. Pregnancy ............................................................................................................... 36
8.5. Causality ............................................................................................................... 36
8.6. Severity ................................................................................................................. 37
8.7. Adverse Event Reporting ...................................................................................... 37
8.8. Foreseeable Adverse Event Reporting ................................................................. 37
8.9. Serious Adverse Event Reporting ......................................................................... 38
9. Statistics ................................................................................................................... 39
9.1. Sample Size ......................................................................................................... 39
9.2. Statistical Analysis ............................................................................................... 39
10. Economic Analysis .................................................................................................. 40
11. Structure and Duration of the Trial ......................................................................... 41
11.1. End of Trial ......................................................................................................... 42

UK Mini Mitral Protocol, Version 3.0, 31st October 2017, REC Number:16/WA/0156, IRAS ID:204506
11.2. Early Trial Cessation ................................................................................................................. 42
11.3. Remuneration ........................................................................................................................... 42

12. Quality Control and Assurance ................................................................................................... 43
12.1. Risk Assessment ....................................................................................................................... 43
12.2. Trial Registration ...................................................................................................................... 43
12.3. Site Initiation and Training ....................................................................................................... 43
12.4. Centre Monitoring and Auditing .............................................................................................. 43
12.5. Blinded Endpoint Review ......................................................................................................... 44
12.6. Serious Breaches ....................................................................................................................... 44
12.7. Ethics ......................................................................................................................................... 44
12.7.1. Good Clinical Practice ........................................................................................................... 44
12.7.2. Approvals ............................................................................................................................... 44
12.8. Information Governance .......................................................................................................... 44
12.9. Retention of Personal Data ...................................................................................................... 45
12.10. Funding .................................................................................................................................. 46
12.11. Insurance ............................................................................................................................... 46

13. Trial Governance ......................................................................................................................... 47
13.1. Centre Research and Development Approval ........................................................................... 47
13.2. Trial Sponsor ............................................................................................................................. 47
13.3. Co-ordinating Centre ............................................................................................................... 47
13.4. Trial Management Group (TMG) ............................................................................................. 47
13.5. Trial Steering Committee (TSC) .............................................................................................. 47
13.6. Principal Investigators’ Meeting (PIM) .................................................................................... 48
13.7. Independent Data Monitoring and Ethics Committee (IDMEC) .............................................. 48
13.8. Expert Panel ............................................................................................................................. 48

14. Protocol Signature ......................................................................................................................... 49
14.1. Principal Investigator Signature .............................................................................................. 49

15. References .................................................................................................................................. 50

16. Contact Details ............................................................................................................................. 59
## 1. Protocol Synopsis

<table>
<thead>
<tr>
<th><strong>Trial Title:</strong></th>
<th>Minimally invasive thoracoscopically-guided right minithoracotomy versus conventional sternotomy for mitral valve repair: a multicentre randomised controlled trial (UK Mini Mitral).</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Internal Reference:</strong></td>
<td>UK Mini Mitral.</td>
</tr>
</tbody>
</table>
| **Trial Design:** | A multi-centre randomised controlled trial of minimally invasive thoracoscopically-guided right minithoracotomy versus conventional sternotomy for mitral valve repair (MVr).  
The trial includes an internal pilot, which will assess the likelihood of meeting the recruitment targets. |
| **Trial Participants:** | Adult patients due to receive isolated MVr for degenerative mitral valve disease. |
| **Inclusion Criteria:** |  
- Adult patients with degenerative mitral valve disease, requiring isolated MVr (patients requiring concomitant Atrial Fibrillation (AF) ablation and Patent Foramen Ovale (PFO) closure will be included).  
- Written informed consent.  
- Fit for cardiac surgery and cardiopulmonary bypass. |
| **Exclusion Criteria:** |  
- Concomitant cardiac surgery other than AF ablation, PFO closure and tricuspid valve surgery.  
- Planned mitral valve replacement.  
- Acute infective endocarditis.  
- Emergency or salvage surgery.  
- Only conventional median sternotomy or only minimally-invasive surgery indicated.  
- Pregnant.  
- Four weeks or more as an inpatient prior to randomisation.  
- Currently participating in another interventional clinical trial.  
- Previous cardiac surgery.  
- Impaired mobility that would preclude SF36-V2 completion |
| **Sample Size:** | 400 patients in total, including those recruited in the internal pilot phase.  
200 patients per treatment arm. |
<p>| <strong>Trial Centres:</strong> | Initially 4 tertiary cardiac surgical units, with additional units added if required following the internal pilot. |</p>
<table>
<thead>
<tr>
<th><strong>Trial Period:</strong></th>
<th>Individual patients will be in the trial for one year following their index surgery. Patients will be consented to long-term follow up using routine data. The main trial, including the internal pilot is anticipated to take 5 years (60 months). For the purposes of notification, the end of the trial is defined as the last visit for the last patient. Serious Adverse Events will be reported from the day of index surgery until 52 weeks following index surgery.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary Objective:</strong></td>
<td>To determine if physical functioning and associated return to usual activities improves in patients who undergo mitral valve repair via minimally invasive thoracoscopically-guided right minithoracotomy compared to conventional sternotomy at 12 weeks. Primary Economic Objective: To estimate if minimally invasive thoracoscopically guided right minithoracotomy compared to conventional sternotomy is more cost-effective at 52 weeks.</td>
</tr>
<tr>
<td><strong>Primary Outcome:</strong></td>
<td>Change in SF-36v2 physical functioning scale (1) at 12 weeks following surgery. Primary economic outcome: incremental cost per QALY gained at 52 weeks following surgery.</td>
</tr>
</tbody>
</table>
| **Secondary Objectives:** | • To explore the feasibility of study recruitment by means of an internal pilot trial; these data will be included in the main data for analysis.  
• To assess cardiac function echocardiographically, with measurements of left ventricular volumes, dimensions and function, mitral regurgitation severity and estimates of both right heart function and pulmonary artery pressure early (3 days to 12 weeks) and late (52 weeks) after surgery, using blinded echocardiography.  
• To compare mitral valve and mitral valve surgery related events and survival (morbidity and mortality) at 52 weeks and at 4.5 years.  
• To compare physical functioning and overall quality of life over 52 weeks post MVr (using SF-36v2(1)).  
• To quantify the level and variability in physical activity and quality of sleep (using an accelerometer (GENEActiv(6-10)) over 52 weeks post MVr).  
• To quantify a range of surgical outcomes over the 52 weeks from index surgery.  
• To compare costs, including intervention-specific estimates, of the two operations in the first 52 weeks following the index operation.  
• To estimate QALYs from responses to the EQ-5D-5L (2-4) and SF-6D (derived from the SF-36v2). |
- To estimate costs to the NHS over 4.5 years.
- To model costs and QALYs up to the end of the patients lifetime.
- To model the incremental cost per QALY gained over the patient lifetime.
- To determine if HES data adequately captures mitral valve related events.

**Secondary Outcomes:**

Internal pilot trial outcomes

- Patient recruitment within the first 6 months of the trial across 4 NHS cardiac surgery centres.

12 week outcomes:

- Level of physical activity.
- Quality of sleep.
- Surgical outcomes (including duration of operation, cardiopulmonary bypass times, protocol adherence).
- Costs, including intervention-specific estimates, of the two operations.
- Mitral valve related events determined using HES, NICOR, and medical record data.
- Left ventricular volumes and function, mitral regurgitation, right heart function, and pulmonary artery pressure.
- Survival.
- Physical functioning using SF-36v2.
- Quality of life using SF-36v2 and EQ-5D-5L.
- Adverse Events and Serious Adverse Events.
- Health care utilisation.
- Wound pain.
- NYHA class.
- Length of hospital stay.
- Concomitant medication.
- Re-operation.
- Conversion (minimally-invasive arm only).
- Red blood cell and blood product transfusions.
- Time on CICU, HDU and ward.
- Duration of ventilation.
- Discharge destination.
- Blood loss following surgery.

One year outcomes:
• Level and variability in physical activity.
• Mitral valve related events determined using HES, NICOR, and medical record data.
• Costs, including intervention-specific estimates, of the two operations.
• Survival.
• Physical functioning using SF-36v2.
• Quality of life using SF-36v2 and EQ-5D-5L.
• Quality of sleep.
• Adverse Events and Serious Adverse Events.
• Health care utilisation.
• Medication usage.
• Quality Adjusted Life Years (QALYs) derived from EQ-5D-5L and SF-36v2.
• Left ventricular volumes and function, mitral regurgitation, right heart function, and pulmonary artery pressure.

Long term outcomes:
• Quality Adjusted Life Years (QALYs) to the end of the patients lifetime.
• Incremental cost per QALY over the patient lifetime.
• Mitral valve related events determined using HES, NICOR and medical records data to 4.5 years.

Process Outcomes:
• Protocol adherence (including protocol violations).
• Fidelity of the operation (including surgeons’ report and local variation).
• Patient withdrawals.
• Conversion from minimally invasive to conventional.

Interventions

Intervention group:

Minimally invasive surgery is by thoracoscopically-guided right minithoracotomy. The patient is intubated with a single or double lumen endotracheal tube. Cardiopulmonary bypass is established by aortic or femoral artery cannulation and venous return is achieved from the venae cavae using a single bicaval cannula placed from the femoral vein or with an additional cannula in the superior venae cava. Transoesophageal echocardiography (TOE) confirms the optimum location of the venous and arterial cannulas.

A 4-7 cm right antero-lateral mini-thoracotomy, is then used to enter the thorax through the third or fourth intercostal space. A soft tissue retractor with or without a small thoracic retractor is utilized to spread the ribs with minimal rib-spreading. The pericardium is opened 3-4 cm anterior and parallel to the phrenic nerve.
from the distal ascending aorta to the diaphragm. A video camera is inserted through a 5-10 mm port.

Endoballoon occlusion or a transthoracic clamp achieves aortic occlusion. Cardiac arrest is achieved with single or repeated doses of cardioplegia. The mitral valve is approached through a paraseptal incision and a left atrial retractor is used to expose the mitral valve.

Following the mitral valve procedure, the left atrium is closed, the heart de-aired and aortic occlusion removed. Cardiopulmonary bypass is then discontinued and the thoracotomy incision closed once haemostasis has been achieved.

**Control group:**

Conventional mitral valve surgery will be performed via a median sternotomy, in which the sternum is divided completely (from the collarbone to the bottom of the breastbone). The operation includes cardiopulmonary bypass established by siting cannulas in the right atrium and inferior venae cava and ascending aorta. The heart is stopped with cardioplegia and the mitral valve is approached via the left atrium. The valve is repaired and assessed intra-operatively by water testing. If the repair is deemed satisfactory, the atrium is closed, de-airing manoeuvres are performed, and the aortic cross clamp is removed to allow reperfusion of the heart. Cardiopulmonary bypass is then discontinued and once haemostasis is performed the sternum is closed.
2. Trial Flow Diagram

Identification of adult patients requiring isolated mitral valve repair surgery for degenerative mitral valve disease

- Consent taken
  - Patients decline involvement \( n = x \)

  - Baseline SF-36v2, EQ-5D-5L, pregnancy test
    - Eligibility confirmed
      - Ineligible \( n = x \)

      - Randomisation \( n = 400 \)
        - Complete further baseline assessments (echo, accelerometer, etc.)

Mitrail Valve Repair via Conventional Sternotomy \( n = 200 \)

Mitrail Valve Repair via Minimally Invasive Thorascopically-Guided Minithoracotomy \( n = 200 \)

Standard Pathway of Care

- Lost to follow up \( n = x \)
  - Withdrawal \( n = x \)

  - Clinical and surgical outcomes during index hospital stay, including pain score \( n = x \)

  - SF-36v2, EQ-5D-5L, accelerometer, pain score, medications, health care utilisation, & clinical outcomes at 6 weeks \( n = x \)

  - SF-36v2, EQ-5D-5L, accelerometer, pain score, medications, health care utilisation, clinical outcomes & echo at 12 weeks \( n = x \)

  - SF-36v2, EQ-5D-5L, accelerometer, health care utilisation, & clinical outcomes at 18 weeks \( n = x \)

  - SF-36v2, EQ-5D-5L, accelerometer, health care utilisation, clinical outcomes at 24 weeks \( n = x \)

  - SF-36v2, EQ-5D-5L, accelerometer, health care utilisation, clinical outcomes at 38 weeks \( n = x \)

  - SF-36v2, EQ-5D-5L, accelerometer, health care utilisation, clinical outcomes & echo at 52 weeks \( n = x \)

  - Long term follow up using HES, NICOR, medical records

  - Analyzed \( n = x \)

- Excluded from analysis (give reasons) \( n = x \)
### 3. Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AE</td>
<td>Adverse Event</td>
</tr>
<tr>
<td>AF</td>
<td>Atrial Fibrillation</td>
</tr>
<tr>
<td>CI</td>
<td>Chief Investigator</td>
</tr>
<tr>
<td>CICU</td>
<td>Cardiac Intensive Care Unit</td>
</tr>
<tr>
<td>CPB</td>
<td>Cardiopulmonary Bypass</td>
</tr>
<tr>
<td>GCP</td>
<td>Good Clinical Practice</td>
</tr>
<tr>
<td>GP</td>
<td>General Practitioner</td>
</tr>
<tr>
<td>HDU</td>
<td>High Dependency Unit</td>
</tr>
<tr>
<td>HES</td>
<td>Hospital Episode Statistics</td>
</tr>
<tr>
<td>HSCIC</td>
<td>Health and Social Care Information Centre</td>
</tr>
<tr>
<td>HTA</td>
<td>Health Technology Assessment</td>
</tr>
<tr>
<td>ICF</td>
<td>Informed Consent Form</td>
</tr>
<tr>
<td>ICU</td>
<td>Intensive Care Unit</td>
</tr>
<tr>
<td>IDMEC</td>
<td>Independent Data Monitoring and Ethics Committee</td>
</tr>
<tr>
<td>IG</td>
<td>Information Governance</td>
</tr>
<tr>
<td>IP</td>
<td>Intellectual Property</td>
</tr>
<tr>
<td>MVr</td>
<td>Mitral Valve Repair</td>
</tr>
<tr>
<td>MVR</td>
<td>Mitral Valve Replacement</td>
</tr>
<tr>
<td>NCTU</td>
<td>Newcastle Clinical Trials Unit</td>
</tr>
<tr>
<td>NHS</td>
<td>National Health Service</td>
</tr>
<tr>
<td>NICOR</td>
<td>National Institute for Cardiovascular Outcomes Research</td>
</tr>
<tr>
<td>NIHR</td>
<td>National Institute for Health Research</td>
</tr>
<tr>
<td>PFO</td>
<td>Patent Foramen Ovale</td>
</tr>
<tr>
<td>PI</td>
<td>Principal Investigator</td>
</tr>
<tr>
<td>PIS</td>
<td>Patient Information Sheet</td>
</tr>
<tr>
<td>QALYs</td>
<td>Quality Adjusted Life Years</td>
</tr>
<tr>
<td>R&amp;D</td>
<td>NHS Trust Research and Development Department</td>
</tr>
<tr>
<td>REC</td>
<td>Research Ethics Committee</td>
</tr>
<tr>
<td>SAE</td>
<td>Serious Adverse Event</td>
</tr>
<tr>
<td>SUSAE</td>
<td>Suspected Unexpected Serious Adverse Event</td>
</tr>
<tr>
<td>TSC</td>
<td>Trial Steering Committee</td>
</tr>
</tbody>
</table>
4. Introduction

4.1. Background

Mitral valve repair (MVr) surgery for mitral valve regurgitation is frequently performed (61) and patient numbers have increased by a third between 2003 and 2012 (from 1,549 to 2118 (31-33)); this rise will continue in an ageing population alongside a recognition in the international guidance that asymptomatic patients may also benefit from early surgery (34,35). Isolated mitral valve repair surgery more than doubled over the same time (681 in 2003 to 1456 in 2012) (31-33).

Left untreated severe mitral regurgitation carries a poor prognosis. In asymptomatic patients the estimated 5-year rates of death from any cause, death from cardiac causes and adverse cardiac events (death, heart failure or new atrial fibrillation), are 22%, 14% and 33% respectively (36). The prognosis for symptomatic severe mitral regurgitation is substantially worse and is further adversely affected by increasing age, atrial fibrillation, pulmonary hypertension, left atrial dilatation, and worsening left ventricular systolic function (37-43).

Mitral regurgitation is most commonly caused by degenerative mitral valve disease, which leads to dilatation of the mitral valve annulus, leaflet prolapse or leaflet restriction. Mitral regurgitation can also be caused by rheumatic valve disease, or infective endocarditis.

In contemporary UK practice, rheumatic mitral valve disease is uncommon and generally found in immigrant populations. The valve is usually not amenable to repair and therefore mitral valve replacement is the most common form of surgical treatment. Similarly, infective endocarditis is relatively rare and generally results in the destruction of the valve tissue; in most cases, optimal surgical treatment requires valve replacement rather than repair.

It is widely accepted that mitral valve repair surgery is the optimal treatment for patients with severe mitral regurgitation caused by degenerative disease. When compared to mitral valve replacement, it carries a lower peri-operative mortality, improved survival, better preservation of left ventricular function and lower long-term morbidity (62-67).

4.2. Choice of Comparators

Mitral valve surgery is routinely performed via a sternotomy incision. Sternotomy involves dividing the sternum completely enabling easy access to the heart and cannulation of the great vessels centrally to establish cardiopulmonary bypass. It allows flexibility in myocardial protection strategies and potentially simplifies de-airing and haemostasis at the end of the procedure.

Disadvantages of a sternotomy incision include an increase in bleeding because of the size of the incision. The mitral valve is posterior to the incision and access to the valve can be difficult. Wound infections occur in 2-3% of patients and significant morbidity, and mortality, can result from this complication (68-72). Importantly, the sternotomy incision is usually closed using multiple stainless steel wires facilitating immobilization of the sternum whilst sternal union occurs. It can take up to 3 months for the sternum to heal completely (44). During this period, the activity of patients is
significantly limited to reduce the risk of sternal dehiscence. These limitations reduce the speed of recovery and limit patients’ ability to return to usual activities including work and physical activities. Moreover, limited activity during this period can increase the risk of complications in the recovery period (45, 46).

Minimally invasive approaches are increasingly used in all surgical specialties. They are often popular with patients, promoted by industry, and are being adopted by surgeons (73-75). In cardiac surgery, minimally invasive approaches are also used for coronary revascularisation (76) aortic valve surgery (77) aortic root surgery (78), and surgery for assist devices (79).

The first minimally invasive mitral valve repair via a lateral thoracotomy was reported in 1996 (81). Initial reports of minimally invasive surgery raised concerns about safety, especially increased incidence of stroke, aortic dissection, peripheral vascular injury, bleeding and increased rates of re-operation due to failed valve repair (81-83).

In more recent reports the safety profile has improved significantly with no significant differences in safety outcomes when minimally invasive surgery is compared to conventional surgery (29, 59). This has predominantly been due to technical improvements, which have simplified the procedure. For example: the aortic endo balloon clamp has been significantly re-engineered to decrease the risk to peripheral vessels (84); improved aortic clamps negate the need to substantially manipulate the aorta (85); and the introduction of automatic knot applicators and pre-measured gortex loops have substantially decreased the time the procedure takes (48). Concurrently operative techniques, including the ability to directly cannulate the aorta, have evolved significantly and decreased complication rates (49, 85).

As a result, there have been several recent publications establishing the safety of minimally invasive mitral valve surgery. Outcomes in a cohort of 1000 patients undergoing minimally invasive mitral valve surgery demonstrated a mortality of 0.8%, and 15-year survival of 79% (25). Of those surviving, freedom from reoperation at 15 years was 90% (25). The approach may also significantly reduce morbidity and mortality in high-risk patients (26) including in the elderly (86). Other data from 1011 patients suggests no difference in mortality or major morbidity, but a reduction in blood transfusions and residual mitral regurgitation following surgery (20); similar findings have been shown in other cohort studies (30). There is also emerging evidence that the minimally invasive approach is less costly than conventional sternotomy; with cost savings driven by reduced intensive care stay and hospital stay as well as reduced need for blood transfusion (16, 22, 23, 27-30, 87).

Five meta-analyses comparing minimally invasive to conventional mitral valve repair have been published (15-19). These all identify only one randomised controlled trial (RCT) reporting short (12) and long term (13) outcomes and base their main conclusions on evidence from observational studies (20-30) which show no significant differences between the two surgical techniques in regard to clinical outcomes. These data show longer cardiopulmonary bypass and cross clamp times, but shorter duration of ICU and overall hospital stay, translating into reduced costs in patients receiving the minimally invasive operation (15-30). Findings also indicate less bleeding and reduced need for
blood transfusion, less pain and wound infection, and an increased risk of aortic dissections from minimally invasive surgery (17). The most consistent finding was that the existing literature is severely limited by the absence of data on comparative outcomes between the two techniques. (15-19) This finding was confirmed through our own review of the available literature. We searched the Cochrane database, and systematically searched PubMed using search terms reflecting those used by cardiac surgeons and reported in the literature: (thoraco OR minithoracotomy) AND (sternotomy) AND (mitral valve OR mitral). We limited the search to those published in English, between 1995 and May 2015. We excluded studies that included patients with non-degenerative mitral valve disease, and that reported more than one third of patients who underwent valve replacement, as well as studies reporting concomitant procedures other than AF or PFO in over one third of patients; this revealed 73 relevant papers. We scrutinized these papers in detail, finding only one small RCT (reporting short and long term follow-up (12,13), 5 meta-analyses (15-19) and 11 observational studies (20-30). There are no relevant studies registered in clinical trial databases, nor any ongoing studies funded by the NIHR.

The one small RCT comparing 140 patients undergoing minimally invasive versus conventional mitral valve surgery was restricted to patients with Barlow’s disease and reported early (12) and 3 year outcomes (13). The trial reported no evidence of a differences in mortality or major morbidity but those receiving minimally invasive surgery had a shorter ventilation time, ICU stay, and lower pain scores. There were no differences in freedom from moderate mitral regurgitation and freedom from repeat surgery from valve failure between groups at one and three-year follow up. Despite this, significant differences were seen in SF-36 scores at 6 months, but this was no longer evident at one year. This trial is severely limited by the very selective diagnosis of the patients included, the small number of patients studied, and the limited detail provided on the primary outcome.

Over the last 5 years, the number of patients undergoing the procedure has increased as some patients and clinicians have realised there are potential benefits of minimally invasive surgery (25, 88-91). This expansion in minimally invasive mitral valve surgery has occurred particularly in Europe and the United States (90, 91), but has been more limited within the UK NHS.

4.3. Current Evidence Supporting the Rationale for the Trial

There is equipoise in the current literature concerning the safety of the two techniques. A RCT is urgently needed to determine whether minimally invasive mitral valve repair surgery should be more widely adopted in the NHS. The International Society of Minimally invasive Cardiac surgery (ISMICS) has recently published a consensus document on the role of minimally invasive mitral valve surgery in contemporary cardiac surgery practice (47). The document highlights the limitations of the evidence they had to consider in reaching a consensus, particularly the lack of adequately powered prospective RCTs to establish the comparative efficacy of the two approaches. Its recommendation was for further prospective RCT, adequately powered to assess quality of life, complications (especially stroke rates), efficacy (repair rates) and clinically relevant outcomes, particularly long term survival, patient functionality and freedom from re-operation (47).
The UK is uniquely placed to perform a RCT of this nature for a number of reasons. At present in the UK, minimally invasive mitral surgery is not standard care, unlike in many centres in the USA and Europe, allowing patients to be recruited and randomised into such a trial. Moreover, there are now an adequate number of cardiothoracic units which have mature minimally invasive mitral valve programs within which such a trial can occur prior to wider adoption of the procedure by the wider community.

There are on-going attempts to concentrate mitral valve repair practice to surgeons and cardiac surgical units who perform a relatively large volume of the procedure (92, 93). There is a unique opportunity for UK mitral valve surgeons to have large volume practices, in dedicated units, in keeping with the current policy for streamlining cardiac services. This context would facilitate investment and uptake of minimally invasive surgery, provided there is evidence to support improved quality of life, cost effectiveness, efficacy, safety, durability of repair, when compared to the conventional sternotomy approach.

Less than 5% of patients having mitral valve surgery in the UK currently have a minimally invasive approach. There are multiple reasons for this; the most important factor is the lack of clear and definitive evidence, from RCT.

There is consensus in the cardiac surgical community that the optimum surgical approach to treat these patients needs to be urgently defined.
5. **Trial Objectives**

The trial will compare two surgical strategies to establish the optimal surgical management of patients requiring mitral valve repair surgery.

The trial will answer the question ‘Are improvements in physical functioning and associated return to usual activities seen in patients who undergo minimally invasive mitral valve surgery compared to conventional surgery?’

5.1. **Primary Objective**

To compare the physical functioning and associated return to usual activities in patients who undergo mitral valve repair via minimally invasive thoracoscopically-guided right minithoracotomy versus conventional sternotomy at 12 weeks.

5.2. **Primary Economic Objective**

To estimate the cost-effectiveness of minimally invasive thoracoscopically guided right minithoracotomy versus conventional sternotomy, estimating the incremental cost per quality-adjusted life year (QALY) gained after 52 weeks.

5.3. **Secondary Objectives**

- To explore the feasibility of study recruitment by means of an internal pilot trial; these data will be included in the main data for analysis.
- To assess cardiac function echocardiographically, with measurements of left ventricular volumes, dimensions and function, mitral regurgitation severity and estimates of both right heart function and pulmonary artery pressure early (3 days to 12 weeks) and late (52 weeks) after surgery, using blinded echocardiography.
- To compare mitral valve and mitral valve surgery related events and survival (morbidity and mortality) at 52 weeks and at 4.5 years (234 weeks).
- To compare physical functioning and overall quality of life over 52 weeks post surgery (using SF-36v2 and EQ-5D-5L(1-4)).
- To quantify the level of physical activity and quality of sleep (using an accelerometer (GENEActiv(6-10)) over 52 weeks post surgery).
- To quantify a range of surgical outcomes over the 52 weeks from index surgery.
- To compare costs, including intervention-specific estimates, of the two operations in the first 52 weeks following the index operation.
- To estimate QALYs from responses to the EQ-5D-5L (2-4) and SF-6D (derived from the SF-36v2) over 52 weeks post-surgery.
- To estimate costs to the NHS over 4.5 years (234 weeks).
- To model costs and QALYs up to the end of the patients lifetime.
- To model the incremental cost per QALY gained over the patient lifetime.
- To determine if routinely collected data adequately captures mitral valve related events.
6. **Trial Design**

6.1. **Summary**

A multi-centre, randomised controlled trial of minimally invasive thoracoscopically-guided right minithoracotomy versus conventional sternotomy for mitral valve repair.

The trial includes an internal pilot phase.

The trial is anticipated to take 60 months to complete and will randomise 400 patients receiving mitral valve repair at participating hospitals in England.

6.2. **Inclusion Criteria**

- Adult (≥18 years old at consent) patients with degenerative mitral valve disease, requiring isolated MVr (patients requiring concomitant surgery for Atrial Fibrillation and/or Patent Foramen Ovale (PFO) closure will be included).
- Written informed consent.
- Fit for cardiac surgery and cardiopulmonary bypass.

6.3. **Exclusion Criteria**

- Concomitant cardiac surgery other than for AF, PFO closure or tricuspid valve surgery (or combinations of these).
- Requiring mitral valve replacement.
- Acute infective endocarditis.
- Emergency or salvage surgery.
- Only conventional median sternotomy or only minimally invasive surgery indicated.
- Pregnant*.
- Currently participating in another interventional clinical trial.
- Four weeks or more as an inpatient prior to randomisation.
- Previous cardiac surgery.
- Patients with existing mobility impairments that would preclude SF36-V2 completion

*Female patients between the ages of 18 and 50 will receive a pregnancy test at baseline.

6.4. **Setting**

The trial will be conducted at UK NHS cardiac surgery units with established minimally invasive and conventional mitral valve services. All centres have the ability to accommodate the needs of this trial including established minimally invasive mitral valve repair services, adequate research nurse support, facilities to carry out the trial interventions and assessments and echocardiographers able to carry out scans (to be reviewed and reported at the lead centre in a blinded manner).

Only units that are in equipoise in the way they manage their patients requiring MVr are able to participate.
6.5. Expertise of Cardiac Surgeons

Each surgeon will perform only one of the operations; either MVr via thoracoscopically-guided right minithoracotomy or via median sternotomy within each centre. Before performing surgery within the trial, each surgeon will have independently completed 50 of these.

Each surgeon will, in advance of the trial starting at their centre, submit a record of the number of operations performed to the Trial Steering Committee.

6.6. Primary Outcome

- Change in SF-36v2 physical functioning scale at 12 weeks following surgery.

6.7. Primary Economic Outcome

- Incremental cost per QALY gained at 52 weeks following surgery.

6.8. Secondary Outcomes

Internal pilot trial outcomes:

- Patient recruitment within the first 6 months of the trial across 4 NHS cardiac surgery centres.

12 week outcomes:

- Level and variability in physical activity.
- Quality of sleep.
- Surgical outcomes (including duration of operation, cardiopulmonary bypass times, anaesthetic regime, protocol adherence).
- Costs, including intervention-specific estimates, of the two operations.
- Mitral valve related events determined using routinely collected data, NICOR, and medical record data.
- Left ventricular volumes and function, mitral regurgitation, right heart function, and pulmonary artery pressure.
- Survival.
- Physical functioning using SF-36v2.
- Quality of life using SF-36v2 and EQ-5D-5L.
- Adverse Events and Serious Adverse Events.
- Health care utilisation.
- Wound pain.
- NYHA class.
- Length of hospital stay.
- Medication usage.
• Re-operation.
• Conversion (minimally-invasive arm only).
• Red blood cell and blood product transfusions.
• Time on ICU, HDU and ward.
• Discharge destination.
• Duration of ventilation.
• Blood loss following surgery.

One year outcomes:
• Level and variability in physical activity.
• Quality of sleep.
• Mitral valve related events determined using routinely collected data, NICOR, and medical record data.
• Costs, including intervention-specific estimates, of the two operations.
• Survival.
• Physical functioning using SF-36v2.
• Quality of life.
• Adverse Events and Serious Adverse Events.
• Health care utilisation.
• Concomitant medications.
• Quality Adjusted Life Years (QALYs).
• Left ventricular volumes and function, mitral regurgitation, right heart function, and pulmonary artery pressure.

Long term outcomes:
• Quality Adjusted Life Years (QALYs) to the end of the patient’s lifetime.
• Incremental cost per QALY over the patient lifetime.
• Mitral valve related events determined using routinely collected data, NICOR and medical records data to 4.5 years.

6.9. Process Outcomes
• Protocol adherence (including protocol violations).
• Fidelity of the operation (including care delivery, surgical and anaesthetic data, and surgeons’ opinion).
• Patient withdrawals.
• Conversion from minimally invasive mini-thoracotomy to conventional sternotomy.

A process evaluation using qualitative and quantitative methods in both arms of the trial will assess the fidelity of both operations. Data from the wide range of surgical and anaesthetic parameters collected as part of the trial will be analysed to assess fidelity. Surgeons will record details of the
operation using a pro-forma to detail their opinion of individual operations including their assessment of the fidelity of the operation to the protocol. To enable rigorous evaluation of each surgical strategy, centres will be asked in a parallel costing exercise about the pathway of care for patients during the trial, including anaesthetic regimens.
### 7. Trial Procedures

#### 7.1. Summary of Trial Assessments

<table>
<thead>
<tr>
<th>Study Procedure</th>
<th>Baseline</th>
<th>Day of Surgery</th>
<th>Index Hospital stay</th>
<th>Follow up – time is calculated from the day of index surgery</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>-26 weeks to day of surgery</td>
<td>Day 0</td>
<td>Day 0 until discharge following index surgery</td>
<td>6 wks</td>
</tr>
<tr>
<td>Consent†</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical History</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical Examination</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Demographics</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Concomitant Medications†</td>
<td>X</td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Pregnancy Test†</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NYHA Class</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ECHO (TTE)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>TOE†</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SF-36v2†</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EQ-50-5L†</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>euroSCORE</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acclerometer</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eligibility Check</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Randomisation</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MVr surgery</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Post-operative details†</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wound Pain score‡</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Ward usage and date of discharge</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discharge destination</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RBC and other blood product transfusions‡</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AEs and SAEs</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Re-operation/further surgery</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Health Care Utilisation Questionnaire</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>HES Data</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>NICOR Data</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Medical Record Review</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

| a) Consent must be taken prior to baseline assessments and confirmation of eligibility. |
b) A list of all medication currently being taken by the patient, including total daily dose, should be recorded.
c) Women between the ages of 18 and 50 must have a negative pregnancy test at baseline.
d) A Transthoracic Echo (TTE) must be performed at baseline if not available within 9 months of surgery. At the time of the TTE, blood pressure and heart rate should be measured, and recorded. One early post-surgical TTE is needed. This can be done from the 1st day post index surgery up to 12 weeks following surgery. A TTE will also be performed one year following index surgery. All TTEs must be transferred electronically to the Core laboratory for analysis as part of the trial.
e) The images from a pre-operative (baseline) TOE should be transferred to the Core laboratory for blinded echo review. The decision of whether or not to do a pre-operative TOE is at the discretion of the operating surgeon.
f) SF-36v2 and EQ-5D-5L should be performed by the blinded observer at The James Cook University Hospital at 6, 12, 18, 24, 38 and 52 weeks following index surgery.
g) Details of the operation will be recorded on the trial surgical pro-forma including the lead surgeon's opinion on fidelity of the operation. Duration of operation, CPB times, need for conversion, and blood and blood product use will be recorded from the medical notes.
h) Total blood loss the time of drain removal following index surgery will be recorded, as well as time of drain removal and duration of ventilation
i) A numerical wound pain rating scale should be used to record pain 3-5 days following index surgery, and at 6 and 12 weeks following index surgery. Analgesic use in the four hours preceding the recording of the pain score should also be noted.
j) The trigger for the RBC transfusion or blood product transfusion will be recorded (e.g. Drop in Hb, bleeding, clinical decision, etc).
7.2. Recruitment

Patients due to undergo isolated MVr surgery at participating centres will be identified at the point of referral (elective patients) and from the inpatient waiting list (urgent but non-emergency patients) by the clinical research team. Patient may be referred through the standard NHS referral pathways; in addition, cardiologists within each region will be made aware of the trial and will be able to refer patients to participating centres.

7.3. Informed Consent

Patients will be sent or given a covering letter and patient information sheet describing the study, and will be seen by one of the research team on the delegation log. The study will be discussed with the patient, and after opportunity for questions, a delegated and trained member of the research team will seek consent. The time between giving the information and taking consent may take a number of weeks. In-house urgent patients may have less time to consider participation however, all steps will be taken to ensure that they are afforded a reasonable time frame to do so and have had all their questions answered prior to consent.

Recruitment will continue until the target sample size is randomised. Patients who decline to participate in this trial will continue to receive care within the department as per usual care.

Written consent for the trial must be taken within 26 weeks (6 months) prior to surgery.

7.4. Eligibility check

Following consent, a consultant cardiac surgeon on the delegation log will confirm the patient’s eligibility prior to randomisation. Surgery should be performed as close to the date of eligibility and randomisation as practicable.

7.5. Screen Failures

Following consent, patients who do not meet trial eligibility criteria prior to surgery will be considered a ‘screen failure’ and withdrawn from the trial with no further data collected.

7.6. Randomisation

Eligible patients will be randomised by delegated and trained members of the research team at each centre using a 24-hour, central, secure, web-based randomisation system with concealed allocation. In the event that the randomisation system is not accessible, the team should contact NCTU.

Eligible patients will be randomised in a 1:1 ratio to undergo MVr using minimally invasive thoracoscopically-guided right minithoracotomy (intervention under study) or conventional median sternotomy (control arm/usual care).

Randomisation will be performed using a minimisation scheme to ensure patients randomised to MVr using minimally invasive thoracoscopically-guided right minithoracotomy (intervention under
study) and conventional median sternotomy (control arm/usual care) are comparable at baseline. The minimisation scheme will account for baseline SF-36v2 physical functioning score (0≤33, >33–≤66, >66)*, - presence or absence of Atrial Fibrillation, presence and severity of tricuspid regurgitation.

*Physical Functioning score is calculated as follows:

Following the completion of the full SF-36v2 the answers to questions 3a to 3j (10 questions in total) should be taken and scored as follows

- 0 to each answer “Yes, limited a lot”,
- 50 to each answer “Yes, limited a little”,
- 100 to each answer “No, not limited at all”.

The 10 scores should be added up to give a value of between 0 and 1000.

This value should then be divided by 10 to give a score between 0 and 100.

For the purpose of randomisation, the baseline SF-36v2 Physical Functioning scores will be grouped into three categories of low (0≤33), moderate (>33–≤66) and high (>66).

This final value should then be used to select the correct SF-36v2 Physical Functioning category in the randomisation system, alongside the patient’s need for concomitant surgery.

7.7. Blinding

The trial will employ a prospective randomised blinded endpoint design; assessments of the SF-36v2 physical functioning scale and overall quality of life questionnaire as well as the EQ-5D-5L assessment will be completed by a blinded assessor at the lead centre.

All echocardiograms will be sent to an independent Core laboratory for assessment by a senior echocardiographer blind to the intervention.

All patients will be asked to consent to both operations and to conversion from minimally invasive thoracoscopically-guided right minithoracotomy to conventional sternotomy if randomised to this arm in the event that conversion becomes clinically indicated.

7.8. Informing General Practitioners of Patient Participation

General Practitioners will be informed of their patient’s decision to participate. A letter providing information about the study and inviting GPs to contact the investigators if they have questions must be sent following consent.

7.9. Withdrawal

Patients may withdraw from the study at any time if they wish to, without giving reason and without any adverse consequences for their future clinical management.
All patients will be made aware of their right to withdraw from the study, and this information will be included in the patient information sheet. Patients will be asked to consent for their continued participation in the event of loss of mental capacity during the trial.

Where possible, and with consent, data will be collected on patients that have withdrawn from the study to ensure completeness of data. Patients who choose to withdraw will be asked: (a) if they are willing for long-term data from their medical records to be collected, and, (b) if the patient withdraws within 12 weeks of surgery, whether they agree to continued data collection to enable the primary endpoint to be answered. If a patient is not in agreement, only data collected to the point of withdrawal will be included in the analysis.

7.10. Baseline Assessments

In addition to usual care procedures, baseline assessments will take place prior to and within 6 months of surgery.

7.10.1. Cardiovascular and Significant Current and Past Medical History

A full medical history will be recorded for each patient at baseline and will include details of all clinically significant past cardiovascular medical conditions and all clinically significant on-going cardiovascular medical conditions. Review of other hospital notes (and GP notes) may be required to complete the medical history.

7.10.2. NYHA Class

NYHA Class assessment will be performed at baseline (at the time of consent) and repeated at 6 and 12 weeks following index surgery.

7.10.3. Physical Assessment

A physical assessment of height (measured in cm), and weight (measured in kg) will take place at baseline to determine Body Mass Index.

Body mass index will be calculated using the following formula:

Weight (kg) divided by height squared (m²)

7.10.4. Current Medications

A list of the generic names of all medications currently taken by the patient, and their total daily dose, will be recorded at four time points during the trial:

- Baseline
- 6 weeks
- 12 weeks
- 52 weeks

7.10.5. Demographic Information

The following demographic data will be recorded as part of the trial:
- age on day of index surgery
- gender
- ethnic group

### 7.10.6. Pregnancy Test

A pregnancy test must be performed in all female patients between the ages of 18 and 50 prior to randomisation. The test must confirm that the patient is not pregnant. Pregnancy testing should be performed at the time of the eligibility check and this should be within one week of randomisation. Should there be a delay in the date of index surgery; pregnancy testing should be repeated within a week of index surgery, as appropriate.

### 7.10.7. Echocardiogram

Cardiac function will be assessed via transthoracic echocardiography (TTE) at baseline, post operatively (1 day to 12 weeks) and at 52 weeks. If an echo has not been done within 9 months of consent, this should be repeated at baseline. At the time of the echocardiogram, heart rate must be measured and recorded. Measurements of left ventricular volumes, dimensions and function, mitral regurgitation severity and estimates of both right heart function and pulmonary artery pressure will be recorded and reported by the Core laboratory.

Valve function may also be assessed pre-operatively and will usually be assessed intra-operatively using a transoesophageal echocardiogram (TOE) as part of usual care in both arms of this trial and to ensure valve integrity prior to closure. Where a pre-operative TOE is performed, the images should be transferred to the Core laboratory. Decisions about TOEs rest with the lead operating surgeon for each case.

All echocardiograms submitted will be assessed by a Core laboratory, led by Dr Richard Graham, at The James Cook University Hospital. Images will be transferred from the study centre to the Core laboratory.

Dr Graham and his team will be blinded to the arm of the study to which patients are allocated. Images will be quality checked in ‘real time’.

All transthoracic echocardiograms will be performed according to the standard British Society of Echocardiography template, and assessed according to the recommendations for the echocardiographic assessment of native valvular regurgitation from the European Association of Cardiovascular Imaging (95).

The UK Mini Mitral Echocardiogram Manual provides further guidance to all centres involved in the study, detailing the number, quality and types of images to be acquired. The Core laboratory will work with centres and their IT services to enable timely transfer of images.

### 7.10.8. Echocardiogram Measures
All images should be provided to the Core laboratory according to the UK Mini Mitral Echocardiogram Manual; the following measures will be reproduced in the Core laboratory and used for secondary endpoint analyses:

- Left ventricular end systolic and end diastolic dimensions by M Mode (2D calliper measurement from parasternal long axis view if perpendiccular M-mode not available)
- Left ventricular end systolic and end diastolic volumes indexed for body size, estimated using Simpson’s biplane method.
- Mitral regurgitation severity – a) vena contracta, b) regurgitant volume by PISA methodology and c) regurgitant fraction
- Left atrial volume by biplane method of discs
- Right ventricular function as assessed by tricuspid annular plane systolic excursion (TAPSE)
- Estimated pulmonary artery pressure from Doppler measurement of tricuspid regurgitation velocity (to estimate right ventricular systolic pressure) and inferior vena cava dimensions (to estimate right atrial pressure)
- All measurements will be the average of 3 sequential beats if in sinus rhythm and 5 sequential beats if in atrial fibrillation, where possible.

Mitral regurgitation will be graded according to the European Association of cardiovascular imaging guidelines from 2013. Mitral regurgitation will be graded as mild, moderate or severe based on quantitative (regurgitant volume, regurgitant fraction and effective regurgitant orifice area) and qualitative (colour Doppler) criteria.

7.10.9. EuroSCORE

EuroSCORE II will be determined prior to surgery, with the score recorded and reported as part of the trial. The elements that determined the euroSCORE II pre-operatively will be recorded.

EuroSCORE II is accessible using the following weblink:
http://www.euroscore.org/calc.html

7.10.10. SF-36v2, EQ-5D-5L

A member of the research team should administer the SF-36v2 and EQ-5D-5L questionnaires to each patient at baseline. The baseline SF-36v2 and EQ-5D-5L questionnaire completion must be prior to randomisation; the SF-36v2 physical functioning scale is used as a stratifying variable. Questionnaire completion will be repeated, by a blinded assessor at the lead centre, at 6, 12, 18, 24, 38 and 52 weeks following the index operation.

The contact details (name, study ID and telephone number(s)) for individual patients need to be securely sent to the Blinded Observer at the Lead Centre by a member of the research team using nhs.net email addresses. Contact details will be used by the Blinded Observer to contact patients at 6, 12, 18, 24, 38 and 52 weeks following surgery.
Members of the research team at participating centres will need to contact the Blinded Observer to confirm the date the patient has their index operation. The Blinded Observer will keep in close contact with participating centres and for all visits, check that it remains appropriate to carry out assessments (SF-36v2 and EQ-5D-5L) at each time-point. Where possible, research team members and the Blinded Observer should co-ordinate their phone calls to minimise disruption to patients who are participating in the trial.

7.10.11. Accelerometer

Participants will be asked to wear an accelerometer on their non-dominant wrist nonstop for 7 consecutive days at seven time-points during the trial (baseline, 6 weeks, 12 weeks, 18 weeks, 24 weeks, 38 weeks, 52 weeks following index surgery).

Patient handedness (right or left handed) must be recorded. Patients should be asked to wear the accelerometer on their other (non-dominant) wrist during the 7 days of measurements. The wrist on which they wear the accelerometer must be recorded.

Accelerometers should be either given to the patient, or sent by post using the specific packaging provided for the trial. Following baseline, patients do not need to attend hospital for the sole purpose of starting or ending a week of accelerometer measurements.

Following the seven days of measurements, accelerometers will be returned in person or by post to the research team at each centre who will download and process the data. The .csv data files will be uploaded to the Case Report Form, with accompanying details, The .csv data files will be kept by the site as source data.

Where a patient is an in-house urgent patient, accelerometer measures will not be possible for 7 days prior to surgery and will therefore not be measured at any time point during the trial for that patient.

Further details about all processes required to enable the accelerometer measures are detailed in the study aids.

7.11. Surgical Interventions

The intervention group will receive mitral valve repair via minimally invasive thoracoscopically-guided right minithoracotomy. The control group will receive MVr via conventional sternotomy.

7.11.1. Conventional Surgery

Conventional mitral valve surgery will be performed via a median sternotomy, in which the sternum is divided completely (from the collarbone to the bottom of the breastbone). The operation includes cardiopulmonary bypass established by siting cannulas in the right atrium and inferior vena cava and ascending aorta. The heart is stopped with cardioplegia and the mitral valve is approached via the left atrium. The valve is repaired and assessed intra-operatively by water testing. If the repair is deemed satisfactory, the atrium is closed, de-airing manoeuvres are performed, and the aortic
cross clamp is removed to allow reperfusion of the heart. Cardiopulmonary bypass is then discontinued and once haemostasis is performed the sternum is closed.

7.11.2. Minimally Invasive Surgery

Minimally invasive surgery is by thoracoscopically-guided right minithoracotomy. The patient is intubated with a single or double lumen endotracheal tube. Cardiopulmonary bypass is established by aortic or femoral artery cannulation and venous return is achieved from the venae cavae using a single bicaval cannula placed from the femoral vein or with an additional cannula in the superior venae cava. Transoesophageal echocardiography (TOE) confirms the optimum location of the venous and arterial cannulas.

A 4-7 cm right lateral mini-thoracotomy, is then used to enter the thorax through the third or fourth intercostal space. A soft tissue retractor with or without a small thoracic retractor is utilized to spread the ribs. The pericardium is opened 3-4 cm anterior and parallel to the phrenic nerve from the distal ascending aorta to the diaphragm. A video camera is inserted through a 5 -10 mm port. Endoballoon occlusion or a transthoracic clamp achieves aortic occlusion. Cardiac arrest is achieved with repeated doses of cardioplegia. The mitral valve is approached through a paraseptal incision and a left atrial retractor is used to expose the mitral valve.

Following the mitral valve procedure, the left atrium is closed, the heart de-aired and aortic occlusion removed. Cardiopulmonary bypass is then discontinued and the thoracotomy incision closed once haemostasis has been achieved.

7.11.3. Concomitant Procedures

Concomitant surgery for Atrial Fibrillation (AF), closure of Patent Foramen Ovale (PFO) and tricuspid regurgitation will be allowed within the trial. Patients will be stratified based on whether they have AF and the grade of tricuspid regurgitation at randomisation.

7.11.4. Anaesthetic Protocol

All patients will receive a standard cardiac anaesthetic. The anaesthetic protocol for individual units will be described during the course of the trial.

The anaesthetic protocol for individual patients does not need recording in the Case Report Form.

7.11.5. Intra-operative Assessments

Details of the operation will be recorded on the trial surgical pro-forma including the lead surgeon’s opinion on fidelity of the operation.
Duration of operation (knife-to-skin time and end of closure time), CPB times, need for conversion, and blood and blood product use (including number of units), will also be recorded.

7.12. Post-operative Assessments

The post-operative period will begin once the patient has been admitted to CICU. Date and time of admission and discharge from CICU will be recorded.

7.12.1. Post-operative Blood Loss

Total blood loss until drain removal, will be measured (in mls) and recorded as part of the trial.

Clinically significant blood loss requiring clinical or surgical intervention should be recorded as an adverse event as part of this trial.

7.12.2. Further Surgery

Any additional cardiac surgery (defined as surgery requiring a General Anaesthetic) following the index operation will be recorded and reported as part of this trial.

Re-operation will be defined as another operation involving the mitral valve.

Conversion will only be recorded in the minimally invasive arm of the trial.

The reason will also be indicated.

7.12.3. Wound Pain Score

Pain will be assessed post-operatively using a numerical wound pain rating scale 3-5 days following index surgery, and at 6 and 12 weeks following index surgery.

At each time-point, the analgesia taken by, or administered to, the patient within the previous 4 hours will be recorded and reported.

7.12.4. Length of Hospital Stay Following Index Surgery

Length of hospital stay following admission for the index operation including cardiac intensive care unit (CICU), and ward (including any HDU) stays should be recorded.

To enable accurate reporting, the date and time of admission and discharge from each ward should be recorded.

7.12.5. Transfusion of Blood and Blood Products

Blood and blood product transfusion in the peri-operative period prior to discharge will be recorded. Indications for transfusions will be in accordance with individual centre protocols. The trigger (e.g.
Hb, coags, bleeding, clinical decision etc.,) for any transfusions should be recorded at the time of transfusion.

7.12.6. Routinely collected data and NICOR Data

Following hospital discharge after the index event, and by agreement with the Health and Social Care Information Centre (HSCIC) we will capture hospital episode statistics (HES) or similar routinely collected data to identify any hospital attendance for mitral valve related events along with HES-linked mortality data. We will also capture these data from the National Institute for Cardiac Outcomes Research database (NICOR). Hospital records will be reviewed by the clinical research teams at each centre to establish how the events identified by routinely collected data and NICOR have been classified. Triangulation and validation in this way is needed because the identification of relevant outcomes has not been previously validated.

The data will be adjudicated and validated by an independent expert panel who will meet yearly throughout the trial. Patients will be asked to consent to long term follow up of these data extending beyond the duration of this trial.

7.12.7. Healthcare Utilisation Questionnaire

A questionnaire will be used to capture primary and secondary care visits following hospital discharge to 52 weeks, and medications prescribed. Patients will be asked to record each visit and the reason for this. Patients will return this at the 6 week visit and receive a telephone call from the research team at 12, 18, 24, 38 and 52 weeks to gather the information.

Where an SAE is foreseeable and requires hospitalisation, the dates of hospitalisation and ward usage should be reported on the CRF for up to 52 weeks following index surgery.

7.13. Follow-up Assessments

At 6, 12, 18, 24, 38 and 52 weeks following index surgery a range of assessments require completion by a member of the research team at each centre.

All assessments, except the accelerometer measurements must be completed within one week, either side, of the scheduled assessment date. Given the accelerometer measurements are for a period of 7 days, measurements may be started up to one week after the scheduled assessment date. Dates of assessments might not coincide with clinic visits, and therefore phone calls to patients at the appropriate time-point will be needed. Unless dates coincide with a planned hospital visit, accelerometers will need to be sent to patients in advance to enable data collection and to avoid the need for unnecessary hospital visits. In the event that a patient does not respond to phone calls, their GP should be contacted to confirm that details for the patient are correct and that it is still appropriate to continue to contact them.

7.13.1. At 6 and 12 Weeks:
Concomitant medications, including total daily dose
NYHA Class
Echo (TTE)*
Accelerometer
Wound pain score
Adverse Events and Serious Adverse Events
Details of any further surgery since the previous assessment
Health Care Utilisation Questionnaire

* One early post-surgical TTE is needed. This can be done from the 1st day post index surgery up to 12 weeks following surgery. All TTEs must be transferred electronically to the Core laboratory for analysis as part of the trial.

At 18, 24 and 38 Weeks:

- Accelerometer
- Adverse Events and Serious Adverse Events
- Details of any further surgery since the previous assessment
- Health Care Utilisation Questionnaire

At 52 Weeks:

- Concomitant medications, including total daily dose
- Echo (TTE)*
- Accelerometer
- Adverse Events and Serious Adverse Events
- Details of any further surgery since the previous assessment
- Health Care Utilisation Questionnaire

* A TTE will be performed one year following index surgery. All TTEs must be transferred electronically to the Core laboratory for analysis as part of the trial.

Patients should be given or sent information packs containing the wound-pain score form, Health care utilisation questionnaire, SF-36v2, EQ-5D-5L and accelerometer details, prior to discharge to facilitate completion of assessments.

Blinded Assessments:

The following assessments will be performed by the blinded assessor for the trial at 6, 12, 18, 24, 38 and 52 weeks, who will phone all patients to complete these:

- SF-36v2
- EQ-5D-5L
8. Safety Reporting

8.1. Adverse Events

Adverse events are defined as any new medical occurrence, or worsening of a pre-existing medical condition in a patient that has received surgery, or procedures associated with the surgery, as part of the trial, which does not necessarily have to have a causal relationship to the surgery, or to procedures associated with the surgery.

The adverse events of wound pain or an event leading to conversion during index surgery are outcomes and as such should not also be recorded as an AE unless they fulfil the criteria for a reportable SAE. The following are also not required to be reported during the trial:

- Haematological and biochemical parameters not deemed to be clinically significant or not requiring clinical intervention.
- Blood loss following surgery unless clinical intervention or further surgery is required.

8.2. Serious Adverse Events

Serious adverse events are defined as any untoward or unexpected medical occurrence that:

- Results in death,
- Is life-threatening,
- Requires hospitalisation or prolongation of existing hospitalisation,
- Results in persistent or significant disability or incapacity,
- Is a congenital anomaly or birth defect,
- Any other important medical condition which, although not included in the above, may require medical or surgical intervention to prevent one of the outcomes listed.

8.3. Foreseeable Adverse Events

Foreseeable Serious Adverse Events are those which are foreseen in the patient population and as a result of the routine care of patients undergoing MVr surgery.

1. death (unless unforeseeable)
2. anaemia
3. anaphylaxis
4. atelectasis
5. atrial fibrillation
6. atrial flutter
7. bowel obstruction or perforation
8. cardiac arrest (where possible, the cause should be recorded as the AE)
9. cardiac pain
10. chest infection
11. collapse (where possible, the cause should be recorded as the AE)
12. deep vein thrombosis
13. dyspnoea (where possible, the cause should be recorded as the AE)
14. endocarditis (including infective endocarditis)
15. gastrointestinal disturbances including gastrointestinal bleeding
16. gut infarction
17. haematoma at surgical sites
18. haemodynamic instability
19. heart block
20. heparin induced thrombocytopenia or other haematological complications
21. hepatobiliary disturbances
22. hypotension
23. infection
24. intra or post-operative bleeding
25. lymphatic leak
26. lymphocele
27. mediastinitis
28. myocardial infarction
29. non-cardiac chest pain
30. oedema (e.g. pulmonary and peripheral)
31. pancreatitis
32. para valvular leak
33. pericardial effusion
34. permanent neurological deficit (stroke);
35. pleural effusion
36. pneumothorax
37. pulmonary embolus
38. renal failure or acute kidney injury
39. respiratory failure
40. sepsis
41. sternal dehiscence
42. sternal malunion
43. sudden ventricular arrhythmias
44. surgical injury (including peripheral vascular injury, lung herniation, diaphragmatic paralysis, and aortic injury)
45. temporary neurological deficit
46. urinary tract infection
47. ventricular fibrillation or tachycardia
48. wound infection
49. wound pain
8.4. Pregnancy

Where a patient becomes pregnant during their involvement in the trial, this must be reported to NCTU using the appropriate form. The pregnancy must be followed until the outcome is known, to determine if an SAE should be reported. Patients who become pregnant should be withdrawn from the trial; pregnancy is likely to have a significant impact on the primary and secondary endpoints within this trial.

8.5. Causality

The relationship of each adverse event to the surgery, and associated surgical procedures, must be determined by a medically qualified individual who is on the delegation log for the trial. The following definitions should be used to determine causality:

<table>
<thead>
<tr>
<th>Unrelated</th>
<th>The event is not considered to be related to the surgery, or procedures associated with the surgery.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unlikely to be related</td>
<td>The event is considered unlikely to be related to the surgery, or procedures associated with the surgery.</td>
</tr>
<tr>
<td>Possibly related</td>
<td>Although the relationship to the surgery, or procedures associated with the surgery, cannot be ruled out, the nature of the event, the underlying disease, concomitant medications or temporal relationship make other explanations plausible.</td>
</tr>
<tr>
<td>Probably related</td>
<td>The temporal relationship and an absence of a more likely explanation suggest that surgery, or procedures associated with the surgery, are the most likely cause.</td>
</tr>
<tr>
<td>Definitely related</td>
<td>The known effects of the surgery, or procedures associated with the surgery, indicate this to be the most likely cause.</td>
</tr>
</tbody>
</table>
### 8.6. Severity

The severity of each adverse event, must be determined by a medically qualified individual who is on the delegation log for the trial. The following definitions should be when determining severity:

<table>
<thead>
<tr>
<th>Grade</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 1</td>
<td>Minor adverse event, not requiring medical intervention. May be asymptomatic and is likely to be a clinical or diagnostic observation only; or may be a symptomatic but minor, or transient event, with no necessity for medical intervention. This might include asymptomatic laboratory or radiographic findings. A minor adverse event is likely to have only marginal clinical relevance.</td>
</tr>
<tr>
<td>Grade 2</td>
<td>An adverse event which may require some medical intervention (local/non-invasive) and which is symptomatic to patient. May affect activities of daily living.</td>
</tr>
<tr>
<td>Grade 3</td>
<td>Significant symptoms reported, requiring medical intervention and possibly requiring hospitalisation. Medically significant and likely to be significantly affecting activities of daily living.</td>
</tr>
<tr>
<td>Grade 4</td>
<td>An adverse event that requires urgent intervention or may have life-threatening consequences.</td>
</tr>
<tr>
<td>Grade 5</td>
<td>Death related to the adverse event.</td>
</tr>
</tbody>
</table>

### 8.7. Adverse Event Reporting

Adverse Events (AEs) will be recorded in the patients’ medical notes and on electronic case report forms. AEs will be recorded from the day of index surgery until 52 weeks following index surgery or until withdrawal, with the exception of adverse events considered related to MVr surgery, which will be followed until resolution, a stable outcome or death.

All AEs will be assessed for severity, causality, and seriousness by an Investigator. All events will be reviewed by the Independent Data Monitoring and Ethics Committee (IDMEC) as part of their ongoing assessment of safety.

### 8.8. Foreseeable Adverse Event Reporting

Foreseeable adverse events should be recorded as adverse events within the trial CRF, but do not require reporting as Serious Adverse Events for this trial.
8.9. Serious Adverse Event Reporting

Unforeseeable SAEs will be reported to Newcastle Clinical Trials Unit and to the Sponsor as soon as the research team become aware of the event, where it is both an SAE and does not appear on the list of foreseeable adverse events. Where required, these events will undergo expedited reporting to the Research Ethics Committee. Unforeseeable SAEs should be reported using the trial specific SAE form.

Where an SAE is foreseeable and requires hospitalisation, the dates of hospitalisation and ward usage should be reported on the CRF.
9. **Statistics**

9.1. **Sample Size**

The primary outcome measure is the change in physical functioning scale within SF-36v2 (1) from baseline at 12 weeks following index surgery. We believe that, on the basis of the literature and consulting with the cardiac and patient community, a minimally clinically important difference is 10 points on the scale. This trial is powered to investigate the superiority of thoracoscopically-guided right mini-thoracotomy over median sternotomy in terms of post-surgical physical functioning assessed using the SF-36v2 physical functioning scale.

One recent publication (13) reports a small variation (standard deviation (SD) of 8) in SF-36 physical function scores; this is not seen in other publications (11, 55) who report a SD of 30. We have therefore used the more conservative estimate to inform the power calculation for this trial.

Assuming alpha of 5% and 90% power, 382 patients (191 in each arm) are required to detect a minimally clinically important difference of 10 points in the SF-36v2(1) physical functioning scale at 12 weeks (assuming a SD of 30 (11)). Patients will be recruited from 4 centres to enable recruitment to target. Allowing for attrition, 400 patients will be randomised.

9.2. **Statistical Analysis**

Data cleaning and analysis will be provided by staff at Newcastle and Durham University. Primary analysis will follow intention to treat principles with patients analysed according to randomisation and irrespective of surgical intervention received; other analysis groups such as per-protocol may be considered subsequently. Every effort will be made to retain and include all patients who are part of the trial.

A full statistical analysis plan (SAP) will be developed for the outcome measures and agreed with the IDMEC and TSC prior to any analysis being undertaken.

Outcome data will be analysed at the end of the study, no interim analyses is planned.

Primary analysis of change in physical functioning as measured using SF-36v2 at 12 weeks using intention to treat principles will use a general linear model accounting for surgical intervention, baseline scores, valve pathology and concomitant surgery. Robust standard error will be incorporated to account for intra-patient correlation due to the repeated measures. A similar modelling approach will be used for the final analysis of change in physical functioning at week 52.

Secondary outcomes: continuous outcomes will be analysed using a general linear model, binary outcomes will be analysed using a generalised estimating equation to account for repeated binary data over time, categorical outcomes (with more than two categories) will be analysed using baseline-category logit model, while log-rank test and frailty modelling will be used to analyse time-to-event outcomes. Analysis of all outcomes with repeated measures on the same patient will account for intra-patient correlation. Multiple imputation will be used if necessary to sensitise incomplete data. All outcomes will also be described using simple statistics to facilitate
interpretations and communication of findings. Secondary analysis will also include hierarchical modelling of patients, surgeons and centres, to provide an estimate of treatment effect at each of these levels.

Each question within the SF-36v2 physical functioning scale will be scored based on the RAND scoring system. The average of the per patient scale scores (assuming each question carries equal weight) will provide the primary outcome for physical functioning at 12 weeks.

10. Economic Analysis

The economic evaluation will include both a within trial; economic evaluation and a modelled based economic evaluation to estimate cumulative costs and QALYs and incremental cost per QALY gained over a patient lifetime. For the within trial economic evaluation patient estimates of costs and QALYs at 52 weeks will be used to estimate the incremental cost-effectiveness of the two surgical procedures, from an NHS perspective. Within the first year, use of NHS services will be collected from medical records, routinely collected data (e.g: HES) and NICOR data and using a patient questionnaire to capture primary and secondary care visits. Use of secondary care health services between month 12 and 55 will be based on data extracted from routinely collected data sources, validated using medical records and the National Adult Cardiac Surgical Database which is administered by The National Institute for Cardiovascular Research (NICOR), adjudicated by an independent expert panel. The role of the independent expert panel will be to assess which use of health services is attributable or sequelae to the index surgery or underlying disease condition (e.g. surgical revision or complication, worsening mitral disease or infection) and/or which is unrelated.

The costs of all health services will be estimated using study specific estimates (the index surgery), and routine data sources e.g. NHS reference costs for other secondary care, PSSRU for primary care and the BNF for medications. For each trial participant we will estimate the total cost of care and then for each intervention group we will estimate incremental mean costs at 12 months. The costs collected over the trial period will be extrapolated beyond the 12 months follow-up to extend to the estimated lifetime of the patients. These results will be reported separately both to illustrate how costs accrue over time and to provide an estimate of total costs up to the patients’ lifetime.

For the within trial economic evaluation QALYs will be estimated from responses to the EQ-5D-5L (2-4) administered at baseline, 6, 12, 18, 24, 38 and 52 weeks post MVr. Responses will be converted into health state valuations using the UK population tariffs. We will use the prevailing population tariffs for the EQ-5D-5L, but responses will be cross walked from the EQ-5D-3L value set (3) following NICE methods guidance, should that still be applicable at the time of analysis.(96) These values will then be used to estimate QALYs for each participant using the area under the curve approach. In a sensitivity analysis, QALYs will also be estimated from responses to the SF-36v2 administered at the same time points. The responses to the SF-36v2 (1) will be converted into SF-6D tariffs and QALYs estimated using the same methodology as described above.
In the within trial economic evaluation the effect of surgery at 52 weeks will be estimated using bootstrapped, bivariate regression modelling of costs and QALYs adjusted for baseline scores and stratifying variables. Bootstrap replicates will be visualised on the incremental cost-effectiveness plane, with a cost-effectiveness acceptability curve and by net monetary benefit, highlighting NICE reference case societal willingness to pay values. Given the timeframe of 52 weeks, discounting of future costs and benefits will not be applied. Multiple imputation will be used if necessary to manage incomplete data, exploring the missing at random assumption and using best practice for imputation. As noted above stochastic sensitivity analysis will be based on the bootstrapped estimates this will be combined with deterministic sensitivity analysis to explore other forms of uncertainty e.g. the use of alternative utility values based on the SF-6D, variation in costs.

We will construct a state transition model to extrapolate beyond the 52 week within trial analysis. The structure of the model will be developed according to best practice guidelines and will describe the patient pathway over their lifetime. Key data to populate the model will come from the within trial analysis. Longer term costs and events, which generate a cost and a routinely collected data record, will be extrapolated from the routine data sources used to estimate costs up to the patients’ lifetime within the economic model. Further data to populate the model will come from structured reviews of the literature e.g. review of the cost-effectiveness registry (https://research.tufts-nemc.org/cear4/Default.aspx) to identify health state utilities for events that occur in the long-term which are not captured within the trial data set. The results of the economic model will be presented as estimates of cost, QALY and incremental cost per QALY gained. As the time horizon is longer than 52 weeks both costs and QALYs will be discounted at the UK recommended rate (currently 3.5%). Probabilistic sensitivity analysis will be used to plot of costs and QALYs on the cost-effectiveness plane, with a cost-effectiveness acceptability curve showing the likelihood that each intervention is cost-effective at different threshold values for society’s willingness to pay. The model will be calibrated with data collected for the trial but which is not directly used in the model (e.g. cumulative estimates of costs or of specific events at 4.5 years derived from the routine records). Both deterministic and probabilistic sensitivity analyses will be conducted to explore key uncertainties.

11. Structure and Duration of the Trial

The total duration of this trial is anticipated to be 60 months; this comprises a 6-month internal pilot and recruitment continuing for a further 37 months of the main trial. Patients will be followed for a minimum of 12 months following index surgery. The trial will randomise 400 patients from participating cardiac surgery centres in the United Kingdom. The final 5 months will comprise final data cleaning, analysis, report writing and dissemination of research findings.

The internal pilot phase, run over a 6 month period in four cardiac surgery centres will assess whether trial recruitment processes and assessments will enable recruitment targets to be achieved.
During the pilot the research team will monitor recruitment and retention at each centre and investigate their processes to identify good practice that can be shared, or, where lower than expected recruitment is seen, determine reasons for this and implement changes to boost recruitment. The research team will talk to clinical team members, current participants, and to patients who have decided not to participate to fully understand the recruitment figures. Where helpful, we will set up meetings between centres to enable sharing of good practice across all participating centres.

The outcomes from the pilot trial will be reviewed by the Independent Data Monitoring and Ethics Committee, and the Trial Steering Committee prior to consideration by the HTA to confirm that the trial should continue.

The duration of trial participation will be from the day of consent until the 52-week follow-up assessments or withdrawal. Where a patient withdraws, but there is a study-related adverse event, this will be followed until resolution, a state of persistence or permanence, or death. All participants will be asked to consent to longer-term follow up using routine data.

The trial will take 60 months to complete. The end of the trial for all participants will be defined as the collection of 52-week outcome data from the last participant.

11.1. End of Trial

The end of the trial will be defined as the last assessment at 52 weeks for the last patient in the trial.

11.2. Early Trial Cessation

If the Sponsor, Lead Investigator, NCTU, IDMEC, TSC, or TMG discover conditions arising during the trial that indicate the trial should be stopped, this action may be taken. The TSC carries the responsibility for deciding if the trial should be stopped early. Conditions likely to warrant study termination include, but are not limited to:

- Futility: the trial has no prospect of reaching its recruitment within the given time frame
- There is a substantial change in understanding/scientific advancement meaning that continuation of the trial is inappropriate
- Safety: overwhelming evidence for harm makes continuation non-viable

11.3. Remuneration

No financial or material incentives will be given to participants, however reasonable travel expenses will be given for participants who return to the hospital for the additional echo assessments.
12. Quality Control and Assurance

12.1. Risk Assessment

NCTU, in collaboration with the Sponsor, has assessed the risk of this trial and will review the risk level regularly throughout the trial.

12.2. Trial Registration

This trial has been registered with the International Standard Randomised Controlled Trial Number database.

12.3. Site Initiation and Training

Initiation visits at each participating cardiac centre will be performed by the Chief Investigator or his delegate and by representatives from NCTU once all appropriate approvals are in place. Specific training will be given to centre staff on use of the randomisation system, eCRF system and accelerometers.

12.4. Centre Monitoring and Auditing

The trial will be monitored by Newcastle Clinical Trials Unit (NCTU) and representatives from NCTU will visit the centres periodically, and in accordance with a trial specific monitoring plan. NCTU representatives will review the quality of the data to confirm that the trial is being run in accordance with the protocol.

NCTU representatives will review the Case Report Forms of patients who sign consent forms for this study, and will compare these directly to the medical notes and source data (a process known as source data verification (SDV)). SDV of consent and full SDV of all data fields will occur for a proportion of patients who enter the trial, chosen at random.

At monitoring visits NCTU staff will also discuss the conduct of the trial with the local trial team and review the Investigator site file.

In addition, the study may be evaluated by an auditor or government inspector, who will also be allowed access to all case report forms, source documents, study files and study facilities.
12.5. Blinded Endpoint Review

This trial has blinded endpoint review of the primary outcome measure and of three secondary outcome measures.

A blinded assessor will conduct SF-36v2 and EQ-5D-5L questionnaire assessments over the telephone for all patients following surgery. Blinded assessments are performed at 6, 12, 18, 24, 38 and 52 weeks following index surgery.

All echocardiograms will be sent securely to the Core laboratory for review and reporting. The Core laboratory team will be blinded to surgical allocation.

12.6. Serious Breaches

A serious breach will be reported to the Sponsor and to the ethics committee as soon as it is identified. Serious breaches are defined as a breach of the protocol which is likely to affect to a significant degree the safety or physical or mental integrity of a trial patient or the scientific value of the trial.

12.7. Ethics

12.7.1. Good Clinical Practice

The trial will be run according to the principles of ICH GCP, and in accordance with relevant UK legislation and the protocol.

12.7.2. Approvals

The trial will not start until a favourable opinion has been given by an NHS REC. In addition, governance approval must be confirmed by NHS Trust Research and Development (R&D) Offices for individual centres prior to starting recruitment.

12.8. Information Governance

The information collected as part of this trial will be stored securely both electronically and on paper and kept confidential. Data will be used according to the provision of the 1998 Data Protection Act, and applicable new regulations, and individuals will not be identifiable through any reports or publications that result from the trial.

Participating patients will be assigned a unique trial number at consent. All paper study files and documents, including personal data and each patient’s consent form will be retained at the participating NHS Trust in a locked office prior to secure archiving at the end of the study. Electronic trial records will be kept on secure NHS servers with access restricted to the study team, these will be securely archived at the end of the trial. Research data will be transferred to Newcastle Clinical Trials Unit, and to Durham and Newcastle Universities for analysis in collaboration with the clinical trial team.

Data will be entered onto an electronic case report form for each patient. Data will be stored on secure servers that are external to both the Sponsoring NHS Trust and to Newcastle University.
Data extracted for review during the course of the trial, and for archiving at the end of the trial, will be stored securely in restricted access areas of Newcastle and Durham University server systems. This data will be accessible to the clinical research team and to Durham and Newcastle University staff, as well as in summary form to members of the TSC, IDMEC, and TMG. Expert panel members may need unique study ID, age, gender and ethnicity when reviewing data; where possible data will be aggregated or fully anonymised. An auditor or regulatory inspector may access trial data, as required. The personal identifiable data on these servers will be encrypted and all data will have access restricted to authorised personnel and be password protected.

The data stored electronically in the database will contain the date of birth, gender, and ethnicity, and assigned trial number for each patient, but no other personal identifiable data. NHS numbers will be recorded and kept by NCTU to enable data to be sent and linked from HES, ONS and NICOR.

Echocardiograms for each patient will be sent to the Echo Core Laboratory. These data will be included in the final research data set for analysis. Consent from individual patients will enable scan data, along with their other fully anonymised trial research data, to be used in future research following the end of UK Mini Mitral.

The Blinded Observer will be sent patient names, unique study ID, date of surgery and preferred contact details to enable follow up for questionnaire completion. These personal identifiable data will be kept securely on NHS servers during the trial, and destroyed at the end of the trial. Any paper copies of completed questionnaires will be securely archived for 15 years following the end of the trial.

Patients who withdraw from the trial will have all data collected up until the point of withdrawal included in the study, except where withdrawal is due to a trial related AE. In this event the patient will be followed until a stable outcome is achieved. Where a patient who has withdrawn agrees, data to answer the primary endpoint of the study can be collected; this will be recorded and used.

Patients who withdraw may also agree to data being collected from routinely collected sources, e.g, HES, ONS and NICOR. Data will be submitted to NCTU and included in the trial analysis.

12.9. Retention of Personal Data

Personal data will be needed to enable follow up of patients, including access to HES, ONS and NICOR data, and to disseminate details of the trial and trial findings to patients.

Personal data will be held securely and confidentially, and will be kept beyond the end of this trial. Follow on funding may be sought to continue to follow patients using routinely collected data. As such, personal data will be kept for 15 years after the last data collection point for all patients, before being confidentially destroyed.
12.10. Funding

This trial has been funded by the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Programme.

12.11. Insurance

NHS Indemnity is in place to cover all aspects of clinical treatment and care provided as part of this trial.

Newcastle University has insurance to cover their contributions to the Trial.

Durham University has insurance to cover their contribution to the Trial.
13. Trial Governance

13.1. Centre Research and Development Approval

Recruitment at each centre will only begin following all applicable approvals.

13.2. Trial Sponsor

South Tees Hospitals NHS Foundation Trust is the trial Sponsor.

13.3. Co-ordinating Centre

The trial will be co-ordinated by Newcastle Clinical Trials Unit - Teesside, Newcastle University, where the Trial Manager will be based.

NCTU will be responsible for the trial database, randomisation, trial management, data management, and statistical analyses. The Chief Investigator and the research teams at each centre will manage the day-to-day running of the trial including recruitment at centres, and in collaboration with NCTU, the training of staff. NCTU will service the trial-related committees and the expert panel.

13.4. Trial Management Group (TMG)

The day-to-day supervision of the trial will be the responsibility of the Trial Management Group, who will report to the Trial Steering Committee. The TMG will meet regularly throughout the trial.

The TMG will consist of:

- The Chief Investigator
- The CTU co-investigators
- The Trial Manager

The Clinical Data Manager, lead Research Nurse, lead statistician, and other members of the co-applicant team may attend TMG meetings, as required.

13.5. Trial Steering Committee (TSC)

NCTU, in collaboration with the Chief Investigator, will organise a trial steering committee (TSC) consisting of an independent chair and at least two other independent members. Independence will be defined as not employed by any organisation directly involved in trial conduct.

Patient representatives, the Chief Investigator, the NCTU co-investigators and other co-applicants will be joined by observers from NCTU. The HTA Programme Manager will be invited to attend all TSC meetings.

The TSC will meet at 6 monthly intervals. The TSC will report to the Sponsor and to the HTA. The TSC will provide overall supervision of the trial, and will monitor progress, conduct and advise on the trial. The TSC will consider the recommendations of the IDMEC, and act where required.
The TSC carries the responsibility for deciding if the trial should be stopped early. Terms of reference for the TSC will be agreed at the first meeting.

13.6. Principal Investigators’ Meeting (PIM)

All Principal Investigators will be invited to an annual meeting to discuss trial progress and to share experiences of conducting the trial at their centre.

13.7. Independent Data Monitoring and Ethics Committee (IDMEC)

NCTU, in collaboration with the Chief Investigator will organise an independent data monitoring and ethics committee (IDMEC). The IDMEC will meet at 6 monthly intervals and will run in accordance with a trial specific DAMOCLES charter (53) which will be agreed at its first meeting.

The IDMEC will report to the TSC and will provide advice on the ongoing conduct and safety of the trial. The IDMEC will review trial outcomes, including adverse events and serious adverse events.

13.8. Expert Panel

NCTU, in collaboration with the Chief Investigator will organise an Expert Panel. The Panel will meet annually to review data from routinely collected sources, e.g., HES, NICOR and medical records, and will run in accordance with terms of reference which will be agreed at its first meeting.

The Expert Panel will comprise three independent clinical experts; they will report to the IDMEC.
14. Protocol Signature

14.1. Principal Investigator Signature

By signing this protocol page, I agree to:

- Conduct the trial in accordance with the protocol
- Personally conduct and supervise the trial and ensure that all colleagues assisting with the trial are appropriately delegated and are informed about their obligations
- Ensure that the requirements with regard to obtaining informed consent are adhered to without exception
- Report all AEs and SAEs that occur during the course of the trial, in accordance with the protocol
- Maintain accurate and complete records to enable confirmation of adherence to the protocol

Principal Investigator’s Signature ___________________________ Date ___________________________
15. References


12. Speziale G; Nasso G; Esposito G; Conte M; Greco E; Fattouch K; Fiore F; Del Giglio M; Coppola R; Tavazzi L. Results of mitral valve repair for Barlow disease (bileaflet prolapse) via right minithoracotomy versus conventional median sternotomy: a randomized trial. Journal of Thoracic & Cardiovascular Surgery. 142(1):77-83, 2011 Jul.

13. Nasso G; Bonifazi R; Romano V; Bartolomucci F; Rosano G; Massari F; Fattouch K; Del Prete G; Riccioni G; Del Giglio M; Speziale G. Three-year results of repaired Barlow mitral


20. Goldstone AB; Atluri P; Szeto WY; Trubelja A; Howard JL; MacArthur JW Jr; Newcomb C; Donnelly JP; Kobrin DM; Sheridan MA; Powers C; Gorman RC; Gorman JH 3rd; Pochettino A; Bavaria JE; Acker MA; Hargrove WC 3rd; Woo YJ. Minimally invasive approach provides at least equivalent results for surgical correction of mitral regurgitation: a propensity-matched comparison. Journal of Thoracic & Cardiovascular Surgery. 145(3):748-56, 2013 Mar.


33. SCTS Blue Book Online - Cardiac Surgery Audit Data bluebook.scts.org The Society for Cardiothoracic Surgery (SCTS) Blue Book


94. EuroSCORE II. http://www.euroscore.org/


16. Contact Details
Newcastle Clinical Trials Unit
Newcastle University
Murray Building, James Cook University Hospital
Middlesbrough
TS4 3BW

T: 01642 854 638
E: nctu.tees@newcastle.ac.uk
W: http://www.ncl.ac.uk/nctu/

UK Mini Mitral is funded by the National Institute for Health Research HTA Programme (project reference 14/192/110)